NCT07610239 Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening
| NCT ID | NCT07610239 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Makerere University |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 24,000 participants |
| Start Date | 2026-03-25 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24,000 participants in total. It began in 2026-03-25 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A cluster randomized trial (CRT) of the novel sickle cell disease (SCD), M-health based SCD Information Management and Communication system SIMCS vs routine new born screening strategy in health care centres in Uganda to evaluate impact on access screening, coordination of care and clinical outcomes
Eligibility Criteria
Inclusion Criteria: Providers of child health and maternity services at selected hospitals Infants born or attending child health and maternity services at selected hospitals . Infants are the targeted age-group in this study because this is the ideal age to screen for SCD and prevent complications and mortality that generally occurs early, by 5 years old. The infants will be recruited at birth or at vaccination visits Exclusion Criteria: * Decline of inability to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07610239 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07610239 currently recruiting?
Yes, NCT07610239 is actively recruiting participants. Contact the research team at mwanjemobo@gmail.com for enrollment information.
Where is the NCT07610239 trial being conducted?
This trial is being conducted at Jinja, Uganda.
Who is sponsoring the NCT07610239 clinical trial?
NCT07610239 is sponsored by Makerere University. The trial plans to enroll 24,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.